{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-005600","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.427636+00:00","generated_at":"2026-05-31T09:18:56.591503+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xenetic Biosciences Q2 net loss $1.3M; cash $7.3M; DNase program advancing","bullets":["Net loss of $1.3M for Q2 2024; R&D expenses flat at $0.9M; G&A up 19.5% to $1.1M on severance.","Royalty payments from Takeda sublicense of PolyXen platform were $0.7M, up 11.6% YoY.","Cash balance $7.3M at quarter end; expected to fund operations into clinical development.","Preclinical studies for DNase oncology platform ongoing; data expected before year end.","Advancing towards Phase 1 clinical proof-of-concept in pancreatic carcinoma and solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-005600","json":"https://secwatch.observer/filing/0001683168-24-005600.json","markdown":"https://secwatch.observer/filing/0001683168-24-005600.md","text":"https://secwatch.observer/filing/0001683168-24-005600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824005600/0001683168-24-005600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824005600/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:18:56.591503+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}